Todos os estudos
RecrutamentoConfirmatório terapêutico (Fase III)Intervencionista

A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria

Phenylketonuria (PKU) is a rare inherited condition where the body cannot properly break down an amino acid called phenylalanine (Phe), which is found in protein. People with PKU must usually stick to a very strict, low-protein diet to protect their brain health. This Phase 3 trial is testing a medicine called PTC923 (sepiapterin). The main goals are to check how safe it is to take over a longer period and to see if it helps the body process Phe more effectively. If successful, it could allow adults with PKU to eat more regular protein. Because this is an 'open-label' study, all participants will receive the active study medicine. Doctors will track side effects, run blood tests, and measure how much dietary protein participants can comfortably tolerate.

Em resumo

Status
Recrutamento
Fase
Confirmatório terapêutico (Fase III)
Patrocinador
PTC Therapeutics Inc.
Meta de inscrição
80
Iniciar
02 Feb 2024

Sobre o que é este estudo?

Phenylketonuria, often shortened to PKU, is a lifelong metabolic condition. People born with PKU lack enough of a working enzyme needed to process phenylalanine (Phe), a natural building block of protein found in foods like meat, fish, dairy, nuts, and even grains. Without strict management, Phe can build up to harmful levels in the blood and brain. Currently, managing PKU often means following a very demanding, low-protein diet and drinking special amino acid supplements every day.

This clinical trial is evaluating an experimental oral medicine called PTC923 (also known as sepiapterin). In the body, sepiapterin turns into a natural substance (BH4) that helps the missing or faulty enzyme work better. The hope is that PTC923 will help people with PKU break down Phe more easily, potentially allowing them to include more everyday protein in their meals.

This is a Phase 3 study, which is the final testing stage before a medicine can be approved for general prescription use. It is also an 'open-label' trial, meaning there is no dummy pill (placebo); everyone who takes part will be given the actual medicine.

Taking part in this research helps scientists understand whether PTC923 is safe over a longer period and whether it genuinely improves daily life and dietary freedom for people living with PKU.

Pontos principais

  • Phase 3 trial assessing the safety and effectiveness of PTC923 (sepiapterin) for PKU.
  • Aims to find out if the treatment allows people to safely eat more natural protein.
  • Open to adults aged 18 and over diagnosed with phenylketonuria.
  • Open-label study, meaning all participants receive the active medicine.
  • Involves regular hospital check-ups, blood monitoring, and dietary assessments.

Quem pode ser elegível?

This study is open to adults aged 18 and older who have been diagnosed with phenylketonuria (PKU). Men and women are both eligible to join.

To take part, you must be able and willing to attend regular clinic appointments, take the study medicine as directed, and follow dietary instructions. This includes keeping track of what you eat during special food assessment periods.

People with certain other unstable health conditions, or those unable to attend regular hospital visits, may not be able to participate. Your PKU specialist or the trial team can confirm your full eligibility based on your medical history.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have a confirmed medical diagnosis of phenylketonuria (PKU).
  3. I am willing to take an experimental oral medication every day.
  4. I can attend regular clinic visits for blood tests and physical health checks.
  5. I am happy to complete food diaries and quality-of-life questionnaires.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Taking part in this study involves taking the study medicine (PTC923) by mouth. You will visit a specialist hospital clinic regularly so doctors can check your general health, record your blood pressure, carry out physical examinations, and take routine blood and urine samples.

A key part of the trial is a dietary assessment. The research team will carefully test how much Phe and natural protein you can safely consume while taking the medicine. You will also be asked to complete short quality-of-life questionnaires to share how you feel day to day and how manageable the treatment is. The trial team will support you throughout the entire study period, which will be explained in detail before you decide to join.

Riscos e benefícios potenciais

Potential benefits may include better control of your blood Phe levels and the chance to eat more natural protein under medical supervision, alongside contributing to research that could help many others with PKU. However, there is no guarantee that the medicine will improve your condition. Potential risks include side effects from the study drug, temporary changes in your blood Phe levels during diet adjustments, and mild discomfort from routine blood tests. Your safety is monitored closely at all times. Taking part is completely voluntary, and you can withdraw from the study at any point without affecting your standard NHS care.

Locations (10)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Países Baixos
  • —
    Não verificado
    Alemanha
  • —
    Não verificado
    Espanha
  • —
    Não verificado
    Itália
  • —
    Não verificado
    Dinamarca
  • —
    Não verificado
    Portugal
  • —
    Não verificado
    Polônia
  • —
    Não verificado
    Chéquia
  • —
    Não verificado
    França
  • —
    Não verificado
    Eslovênia

Perguntas frequentes

What is the main goal of this trial?

The study aims to check the long-term safety of PTC923 and see if it helps adults with PKU tolerate more protein in their everyday diet.

Will I definitely receive the real medicine?

Yes. This is an open-label trial, so there is no placebo (dummy medicine). All participants receive PTC923.

Do I have to change my diet immediately?

No. Any dietary changes or protein increases will be carefully guided and monitored step-by-step by the trial's metabolic dietitians.

Posso sair do estudo se mudar de ideia?

Yes. You have the right to withdraw from the trial at any time, for any reason, and your normal medical care will continue as usual.

Does taking part cost anything?

No. The study medication and all trial-related tests are provided free of charge, and travel expenses to clinic visits are usually reimbursed.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenyl…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.